Emgality Market Report 2026

Emgality Market Overview

• The Emgality market growth in the historic period has been driven by high migraine prevalence rates, unmet needs in chronic migraine care • Market expansion is supported by growth in chronic migraine population, expansion into new headache indications • Growth Driver: Increasing Prevalence Of Migraine Driving Demand For The Emgality Market • Market Trend: Strategic Partnerships Boosting Market Expansion In Migraine Treatment • North America was the largest region in 2025.

What Is Covered Under Emgality Market?

Emgality is a prescription medication used for the prevention of migraines and the treatment of episodic cluster headaches in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in migraine attacks and pain pathways. The main types of emgality clinical indications are migraine prevention and cluster headaches. Migraine prevention focuses on minimizing the frequency and intensity of migraine episodes through approaches such as CGRP blockers, lifestyle modifications, and prophylactic medications. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and used by several end users, including hospitals, clinics, ambulatory care, and home care.

What Is The Emgality Market Growth Forecast?

The growth in the forecast period can be attributed to growth in chronic migraine population, expansion into new headache indications, increasing biologic drug acceptance, improved patient adherence, rising neurology healthcare spending. Major trends in the forecast period include rising adoption of cgrp inhibitors, shift toward preventive migraine therapies, growing demand for long term headache control, expansion of biologic neurology treatments, patient preference for monthly injections.

Global Emgality Market Segmentation

1) By Clinical Indication: Migraine Prevention, Cluster Headaches 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Is The Driver Of The Emgality Market?

The increasing prevalence of migraine is expected to propel the growth of the emgality market going forward. A migraine is a neurological disorder characterized by intense, throbbing headaches often accompanied by symptoms such as nausea, sensitivity to light and sound, and sometimes visual or sensory disturbances known as auras. The prevalence of migraine is attributed to factors such as rising stress levels, lifestyle changes, environmental triggers, and greater awareness and diagnosis of the condition. Emgality prevents migraines by blocking the calcitonin gene-related peptide (CGRP), reducing the frequency and intensity of attacks. This treatment offers long-term relief, improving quality of life and minimizing migraine-related disability in frequent sufferers. For instance, in May 2023, according to Migraine Canada, a Canada-based organization dedicated to supporting individuals affected by migraines, migraines affect 12% of Canadians (4.5M) and over 1 billion globally, with higher prevalence in women (30% lifetime) compared to men (8%) and children (10%). One in four households is impacted, with 1-2% suffering chronic migraines. Therefore, the increasing prevalence of migraine will drive the growth of the emgality industry.

Key Players In The Global Emgality Market

Major companies operating in the emgality market are Eli Lilly and Company

Global Emgality Market Trends and Insights

The key trend in the emgality market is strategic partnership approach that enhance technology integration and expand market reach. A strategic partnership typically refers to a collaborative relationship between two or more organizations combining their resources, expertise, and efforts to achieve common goals or objectives. For instance, in December 2023, Organon & Co., a US-based healthcare company with a focus on women's health, expanded its partnership with Eli Lilly to broaden access to the innovative migraine treatments, Emgality and RAYVOW, throughout Europe, utilizing Organon's expertise in central nervous system disorders and established commercial capabilities. The partnership explicitly targets the significant impact of migraines on women and strengthens Organon's portfolio in women's health. Organon will oversee the distribution and promotion of the products, while Lilly will maintain manufacturing and marketing authorization, ensuring the effective delivery of these essential treatments.

What Are Latest Mergers And Acquisitions In The Emgality Market?

In January 2023, AffaMed Therapeutics, a China-based clinical-stage biopharmaceutical company, partnered with Eli Lilly and Company. The partnership seeks to introduce Galcanezumab in China as a preventive treatment for episodic migraine, addressing critical medical needs and enhancing patients' quality of life while bolstering AffaMed's neurology portfolio and market presence. Eli Lilly and Company is a US-based pharmaceutical company that manufactures Emgality.

Regional Insights

North America was the largest region in the emgality market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Emgality Market?

The emgality market consists of sales of injections, prefilled syringes, and auto-injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Emgality Market Report 2026?

The emgality market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the emgality industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.